Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.14 +2.47%

+$0.76 today

Market cap
$365.67M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.25M

Average 0.16M

NGNE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Neurogene Inc.NASDAQ: NGNE

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$30.08M, compared with -$21.88M a year earlier. Trailing-twelve-month EBITDA was -$95.45M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of -$123.45M (-41.5%) for the fiscal year ending Dec 2026, a slowdown from the -21.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$30.08M-25.6% QoQ
Last fiscal yearDec 2025
-$87.25M-21.4% YoY
LTMMar 2026
-$95.45M-22.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.5%——
1 year-21.4%-41.5%-20.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(87.25M) USD
Year-over-year change
-21.4%
Reported Analyst consensus estimate

EBITDA vs competitors

How NGNE compares with its peers on the latest reported figures

  • NGNE's LTM Mar 2026 EBITDA of -$95.45M is the 3rd highest of the 8 companies compared; the peer median is -$112.54M.
  • Its year-over-year change of -22.9% is the 5th highest of 8, against a peer median of -1.3%.
NGNE Competitors Peer median
EBITDA for NGNE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DSGNDesign Therapeutics, Inc.LTM Mar 2026-$69.09M -24.3%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$85.19M +20.5%——
NGNENeurogene Inc.LTM Mar 2026-$95.45M -22.9%——
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M +32.5%—120.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$112.54M -37.5%—308.4%
ALECAlector, Inc.LTM Mar 2026-$116.42M -1.3%—632.1%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-$148.77M -62.6%—2712.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
Peer median (excluding NGNE) -$112.54M-1.3%—308.4%

Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000925K0
Cost of Revenue42.26M3.2M3.26M3.25M3.19M
Gross Profit(42.26M)(3.2M)(3.26M)(2.32M)(3.19M)
Gross Margin———-251.0%—
Research & Development42.26M47.51M44.39M60.92M75.01M
Selling, General & Admin8.27M9.01M11.19M22.61M25.13M
Operating Expenses8.27M53.32M52.32M80.28M100.02M
Depreciation & Amortization947K3.2M3.3M3.25M3.09M
EBITDA(49.57M)(51.99M)(33.01M)(71.89M)(87.25M)
EBITDA Margin———-7771.4%—
Operating Income(50.53M)(56.52M)(55.58M)(82.61M)(103.21M)
Operating Margin———-8930.3%—
Interest Income19K1.34M2.95M8.47M11.55M
Interest Expense02K12K12K5K
Other Income / Expenses17K1.33M19.27M7.46M12.86M
Income Before Tax(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Pre-Tax Margin———-8123.7%—
Income Tax Expense00000
Net Income(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Net Margin———-8123.7%—
EPS (Basic)(0.92)(4.30)(2.83)(4.28)(4.24)
EPS (Diluted)(0.92)(4.30)(2.83)(4.28)(4.24)
Weighted Avg Shares55.04M12.82M12.82M17.57M21.17M
Weighted Avg Shares (Diluted)55.04M12.82M12.82M17.57M21.17M

Neurogene Inc.

NASDAQ:NGNE

Intrinsic Alpha fair value

Locked

Current Price

$23.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.